WIXOM,
Mich., May 23, 2022 /PRNewswire/ -- Rockwell
Medical, Inc. (Nasdaq: RMTI) ("Rockwell Medical" or the "Company"),
a biopharmaceutical company dedicated to transforming the treatment
of iron deficiency and anemia management, today announced that
Russell Ellison, M.D., M.Sc.,
President and Chief Executive Officer is scheduled to present at
H.C. Wainwright's Annual Global Life Sciences Conference in
Miami, Florida on Tuesday, May 24th at 3:30 PM ET.
A video webcast of the presentation will be available the
following day in the "Investors" section of the Company's website
at www.rockwellmed.com, and will be archived on the Company's
website for 90 days.
About Rockwell Medical
Rockwell Medical is a commercial-stage biopharmaceutical
company developing and commercializing its next-generation
parenteral iron technology platform, Ferric Pyrophosphate Citrate
(FPC), which has the potential to lead transformative treatments
for iron deficiency in multiple disease states, reduce healthcare
costs and improve patients' lives. The Company has two FDA-approved
therapies indicated for patients undergoing hemodialysis, which are
the first two products developed from the FPC
platform. Rockwell Medical is also advancing its FPC
platform by developing FPC for the treatment of iron deficiency
anemia in patients outside of dialysis, who are receiving
intravenous medications in the home infusion setting. In
addition, Rockwell Medical is one of two major suppliers
of life-saving hemodialysis concentrate products to kidney dialysis
clinics in the United States.
For more information, visit www.RockwellMed.com.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/rockwell-medical-inc-to-present-at-hc-wainwright-annual-global-life-sciences-conference-301552591.html
SOURCE Rockwell Medical Technologies, Inc.